← Back to patent-cliff list
AZD-2265
Tier C — Watch / tradeAZD-2265
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Castration-resistant prostate cancer, Prostate cancer
Regional status
US
Phase III
2026-05-04
EU
Phase III
2026-05-04
China
Phase III
2026-05-04
Japan
Phase III
2026-05-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AZD-2265?
Approved indications include: Castration-resistant prostate cancer, Prostate cancer.
When does the AZD-2265 patent expire?
No public expiry year is available for AZD-2265 yet; this page updates once verified.
How do I get a quote for AZD-2265 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29